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To the editor, 
 
Gastric or gastroesophageal junction (GEJ) adenocarcinoma represents a major health issue, being  
the 3rd cause of death by cancer in the world. In industrialized countries, the incidence of GEJ 
cancers continues to rise, while gastric cancers have declined over the past few decades. 
The human epidermal growth factor 2 (HER2) gene is a well-described proto-oncogene. HER2 
gene amplification and protein overexpression have been mostly studied in breast cancer, where 
HER2 overexpression was reported in 15-20% of cases. 
In breast cancer, HER2 overexpression is associated with a higher risk of brain metastases and 
significantly worse survival [1].   
The prognostic value of HER2 overexpression in gastric and GEJ adenocarcinomas remains 
controversial. A recently published systematic review was inconclusive in patients after curative 
surgery [2]. The standard of care in advanced gastric carcinoma patients has changed recently, 
with the results of the ToGa phase III trial adding trastuzumab to chemotherapy in patients with 
HER2 overexpression [3]. The study indicated that this subgroup of patients benefit from 
trastuzumab with a three months improvement of overall survival. 
The aim of this study was to seek if the correlation between HER2 overexpression and brain 
metastases exists in gastric or GEJ adenocarcinomas, where brain metastases are uncommon. 
 
Materials and methods 
Patients 
We collected retrospectively clinical and histological data on patients treated between 2007 and 
2011 for metastatic gastric,  GEJ or lower third esophageal adenocarcinoma from hospital medical 
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charts of our institution. Data included location of the primary tumor, TNM staging, histological 
subtype, adjuvant chemotherapy and/or radiotherapy, time to recurrence, site of metastases, 
treatment of metastatic disease, occurrence of cerebral localization, chemotherapy regimens, 
response to treatment, time to tumor progression and overall survival. 
 
Immunohistochemistry 
IHC were assayed on 4 µm sections of formalin-fixed paraffin-embedded tumor tissues 
using primary polyclonal antibody A085 (Dako) using standard methodology. Cases were 
considered positive if scored 3+, negative if scored 0 to 1+, FISH was performed in cases 
scored 2+ by IHC [4]. 
 
Fluorescent in situ hybridization 
Interphase FISH analysis was performed on 4 µm sections of formalin-fixed paraffin-embedded 
tumor tissues using the PathVysion HER-2 DNA Probe Kit (Abbott Molecular, Rungis, France). 
Cases were considered positive if the ratio HER2 (17q11.2-12) / CEP17 (17p11.1-q11.1 Alpha 
Satellite DNA) was superior to 2.2 [4].  
 
Statistical methodology 
We compared the frequency of brain metastases from two groups, one HER2+ and the other HER2-
, with Fisher’s exact test. Survival analysis was performed by the Kaplan-Meier method for overall 
survival (OS) and progression-free survival (PFS).  
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Results 
 
Between 2007 and 2011, 74 patients were treated for metastatic gastric or GEJ adenocarcinoma at 
our institution, and HER 2 status could be analyzed in 63. Eleven patients were excluded for missing 
histopathological data. 
 
Demographic and clinical characteristics of patients are summarized in Table I.  
Eleven (18%) specimens were HER2-positive (HER2+). Status were obtained by 
immunohistochemistry in 58 patients, FISH in 5. The median age was 62 years (range: 22-81), there 
were 52 men (83%) and 11 women (18%). Thirty-six patients (57%) had a gastric tumor, 27 (43%) 
tumor of the GEJ. After a median follow up of 9.4 months, 52 patients showed progression, and 38 
patients died. All patients had chemotherapy either initially or at the time of metastatic evolution. 
Median PFS was 5.3 months and median OS was 15.9 months. Thirty-eight patients (60%) had liver 
metastases, 32 (51%) lymph node metastases, 20 (32%) peritoneal carcinomatosis, 12 (19%) lung 
metastases and 3 (5%) brain metastases. 
Two patients HER2+ did not receive trastuzumab because their treatment was performed before the 
result of the TOGA study. In the 11 patients HER2+, 3 (27%) had brain metastases, versus 0 (0%) 
in the 52 HER2- patients (Fisher’s exact test p = 0.004). Brain metastases were all discovered after 
appearance of neurological symptoms (motor deficit, headache, and stroke). One occurred during 
treatment with trastuzumab. The control of brain metastases was obtained in all 3 patients with a 
multimodal treatment (surgery for one patient, radiotherapy for 3 patients and chemotherapy 
associated with trastuzumab for 3 patients). One of the patients was polymetastatic, and the other 
two had either lymph node or liver metastases. The response to treatment of brain lesions was 
heterogeneous with one partial response, and two stable disease. 
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Moreover, peritoneal carcinomatosis was diagnosed in 20 of the 52 (39%) HER2- patients versus 0 
of 11 (0%) HER2+ patients (p = 0.013). There was no association between HER2 status and other 
sites of metastases, and no association between brain or peritoneal carcinomatosis and other factors 
(gender, age, T and N stage). 
We studied PFS and OS as an exploratory analysis, due to small numbers. PFS was significantly 
better among HER2 + patients treated with trastuzumab than in patients with HER2-: median 9.4 
months against 5.0 months (p = 0.041) (Figure 1). The respective median OS was not reached and 
10.9 months, but the difference was not statistically significant (p = 0.057) (Figure 1).  
 
Discussion 
The prognostic value of HER2 gene amplification and protein overexpression in gastric 
adenocarcinoma is not as clear as in breast cancer. The largest study to date with 900 cases found 
that HER2 expression in gastric cancer was not correlated to prognosis. In this study less than 10% 
of all gastric cancer expressed HER2 [5]. In a review of the 35 studies reporting the impact of HER2 
overexpression on survival, 44% of patients had TNM stage I/II, and 56% had TNM stage III/IV 
disease. Twenty studies (57%) reported no difference in overall survival, two studies (6%) reported 
significantly longer overall survival in patients with HER2 overexpression and 13 studies (37%) 
reported significantly poorer overall survival in patients with HER2 overexpression [2]. Overall it 
appears difficult to determine to the prognostic value of HER2 overexpression.  
In breast cancer, HER2+ patients had an increased risk of brain metastases [6,7], and the 
development of central nervous system (CNS) metastases in breast cancer is associated with poor 
prognosis [6]. However, to date similar data on HER2+ gastric adenocarcinoma and brain 
metastases are still lacking. In this retrospective single-center series, we tried to offer some 
preliminary data. We showed increased incidence of brain metastases in patients with HER2+ 
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gastric or GEJ adenocarcinomas. Three HER2+ patients had cerebral metastases, as compared with 
HER2- (p = 0.004). Another previously unreported finding of this study is the less frequent 
peritoneal carcinomatosis in the HER2+ group. This could be related to the fact that HER2 
overexpression is less frequent for diffuse type gastric cancer [2]. Diffuse-type gastric cancer have 
been associated with more frequent peritoneal carcinomatosis. These differences in pattern of 
metastases are probably under the dependence of different biological behavioral, which may gain 
importance in the next years for decision-making. 
Limits of our study are clearly its monocentric nature and the small number of patients. Our results 
should be replicated by other group. However, in the current study, all histological specimens were 
assessed for HER2 status as recommended by Rüschoff et al, with initial IHC testing and 
FISH/silver in situ hybridization to re-evaluate samples with an IHC score of +2 [4]. 
In conclusion, in this single-center retrospective study, we showed an increased incidence of brain 
metastases in patients with HER2 + gastric or GEJ adenocarcinomas, and a decreased incidence of 
peritoneal carcinomatosis. The prognosis of patients HER2 + treated with trastuzumab seems better 
than that of patients HER2-. These results should be confirmed in a multicenter study. The possible 
consequence in this population would be the necessity of a systematic search for brain metastases. 
 
Conflicts of interest: none to declare 
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Figure Legend: 
 
 
Figure 1: Progression-free survival (A) and overall survival (B) for patients treated with and 
without trastuzumab 
 
 
